Caxton Associates (New York)’s Kindred Biosciences, Inc. KIN Stock Holding History

Caxton Associates (New York)’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,713	Closed	-$107K	–	649
2021 Q2	$107K	Buy	+11,713	New	+$68.1K	0.01%	448

Other funds holding KIN

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Caxton Associates (New York)'s KIN Position: Q3 2021 in Review

Caxton Associates (New York) sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 11,713 shares — an estimated $107K sold.

Caxton Associates (New York) first reported a position in KIN in Q2 2021 and held it in 1 quarter. The position peaked at $107K in Q2 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

Caxton Associates (New York) reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
Caxton Associates (New York) sold 11,713 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $107K.
Caxton Associates (New York) first reported a position in Kindred Biosciences, Inc. in Q2 2021 and held it in 1 quarter.
Caxton Associates (New York)'s Kindred Biosciences, Inc. position peaked at $107K in Q2 2021.
1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Caxton Associates (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.